Statistics from Altmetric.com
Randomised controlled trial.
Follow up period:
Two hospital inpatient units, Taiwan, from January 2000 to July 2003.
Sixty five people aged 18–60 years with acute exacerbation of DSM-IV schizophrenia (45% female). Exclusions: baseline Positive and Negative Syndrome Scale (PANSS) total score <60; abnormal urine, blood, biochemical, or electrocardiography results; substance abuse or dependence; smoker; received atypical antipsychotic; contrainidication to antipsychotics; or received depot antipsychotic in previous six months.
D-serine (2 g/day) plus risperidone (titrated to 6 mg/day); sarcosine (2 g/day) plus risperidone; placebo plus …
For correspondence: Guochuan E Tsai, Department of Psychiatry, Harbor-UCLA Medical Center, 1000 W Carson Street, Torrance, CA 90509, USA;
Sources of funding: National Science Council, National Health Research Institutes and China Medical University, Taiwan, and the National Alliance for Research on Schizophrenia and National Institute of Mental Health, USA.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.